DefiniGEN provide disease modelled neonatal diabetes human pancreatic cells which are highly functional CRISPR gene-edited human pancreatic cells. Neonatal diabetes mellitus (NDM) is a rare but potentially devastating metabolic disorder characterized by hyperglycemia combined with low levels of insulin. The neonatal diabetes cell products display the disease phenotype in combination with general function comparable to human primary pancreatic islets. These cell products can offer disease modelling and drug discovery researchers unprecedented tool for elucidating the underlying mechanisms of this key form of monogenic diabetes.
- Highly standardized cell product containing >97% human pancreatic cells with consistent performance and biologically relevant data
- Disease circuit verified confirmed mutation in KCNJ11 gene encoding Kir6.2 subunit of potassium channels – CAT>CGT at codon 201
- Phenotypic analysis of the cells using GSIS assays demonstrates that the insulin response to glucose challenge is dysfunctional in these disease modelled cell products in contrast to DefiniGEN’s isogenic wild-type control pancreatic cell products.
|Product ID||Def-PANC KCNJ11|
|Cell number||10 million viable cells|
|Genetic background||KCNJ11 Neonatal Diabetes|
|Pricing||Request a quote|
Pancreatic Cell Morphology
Def-PANC WT cells and Neonatal disease model variants display typical pancreatic cell morphology.
Disease Circuit Verification
Neonatal Diabetes disease model with confirmed mutation in KCNJ11 gene encoding Kir6.2 subunit of potassium channels – CAT>CGT at codon 201 – isogenic control available
Glucose Stimulated Insulin Secretion Assay
Def-PANC Neonatal diseased modelled cell products display dysfunctional GSIS results in contrast to wild-type Def-PANC cells which exhibit an effective GSIS response.